IRIS
MARCHETTI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.261
EU - Europa 3.628
AS - Asia 1.942
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 8
SA - Sud America 5
AF - Africa 3
Totale 9.857
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.247
CN - Cina 745
UA - Ucraina 696
IE - Irlanda 649
SG - Singapore 635
IT - Italia 521
SE - Svezia 460
GB - Regno Unito 408
TR - Turchia 392
FR - Francia 310
DE - Germania 232
FI - Finlandia 139
RU - Federazione Russa 121
IN - India 119
CZ - Repubblica Ceca 28
BE - Belgio 24
HK - Hong Kong 14
CA - Canada 13
NL - Olanda 12
EU - Europa 10
IL - Israele 9
VN - Vietnam 9
GR - Grecia 5
JP - Giappone 5
NZ - Nuova Zelanda 5
IR - Iran 4
NO - Norvegia 4
PL - Polonia 4
AU - Australia 3
PK - Pakistan 3
RO - Romania 3
TW - Taiwan 3
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
DK - Danimarca 2
ES - Italia 2
KR - Corea 2
MK - Macedonia 2
NG - Nigeria 2
BR - Brasile 1
LU - Lussemburgo 1
MN - Mongolia 1
MX - Messico 1
NP - Nepal 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.857
Salva come PNG Salva come JPEG
Città #
Jacksonville 843
Chandler 823
Dublin 641
Singapore 575
Princeton 323
Southend 288
Izmir 239
Nanjing 239
Ashburn 169
Beijing 150
Santa Clara 140
Wilmington 137
Cambridge 132
Dearborn 120
Altamura 108
Ann Arbor 90
Boardman 89
Nanchang 71
Chieti 69
Shenyang 53
New York 45
Hebei 39
Tianjin 39
Los Angeles 35
Woodbridge 35
Kunming 31
Hangzhou 26
Rome 26
Grevenbroich 25
Washington 25
Norwalk 22
Brussels 20
Jiaxing 20
San Mateo 20
Pescara 19
Augusta 18
Collecorvino 18
Helsinki 18
Milan 18
Brno 17
Orange 16
Munich 14
Latina 13
Changsha 12
Hong Kong 12
Jinan 11
Fairfield 10
Falls Church 10
Ningbo 10
Toronto 10
Dong Ket 9
Lanzhou 9
Tappahannock 9
Andover 8
Chicago 8
Montesilvano 8
Olomouc 8
Varallo 8
Zhengzhou 8
Auburn Hills 7
Seattle 7
Houston 6
Leawood 5
Cavacurta 4
Hanover 4
London 4
Milazzo 4
Verona 4
Changchun 3
Civitanova Marche 3
Edinburgh 3
Florence 3
Frankfurt am Main 3
Gloucester 3
Guangzhou 3
Hefei 3
Oslo 3
Reggio Emilia 3
Saint Louis 3
Taizhou 3
Valduggia 3
Walnut 3
Antwerp 2
Aprilia 2
Arielli 2
Auckland 2
Bari 2
Carmignano 2
Clearwater 2
Council Bluffs 2
Eden Prairie 2
Frankfurt 2
Fuzhou 2
Gent 2
Hyderabad 2
Islamabad 2
Karasawa 2
Klausen 2
Lagos 2
Las Vegas 2
Totale 6.131
Salva come PNG Salva come JPEG
Nome #
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 131
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 116
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 112
A multidisciplinary group for prostate cancer management: A single institution experience 111
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 103
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 103
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 102
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. 99
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 97
A unique microRNA signature associated with ischemic stroke in humans 96
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 95
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 95
Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non–Small-cell Lung Cancer: Clinical and Budget Effect 93
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 92
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 91
HIGH-RISK HUMAN PAPILLOMA VIRUS INFECTION, TUMOR PATHOPHENOTYPES AND BRCA1/2 AND P53 STATUS IN JUVENILE BREAST CANCER PATIENTS. 90
A unique microRNA signature associated with plaque instability in humans. 90
Evaluation of DNA Base Excision Repair and ErbB signaling in euthyroid goiters 89
Analysis of DNA Glycosylases MUTYH and OGG1 and Their Correlation with EGFR Signalling in Normal and Nodular Thyroid Tissues 89
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 88
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 87
Primary pleuro-pulmonary synovial sarcoma: a single-center 13-year experience 86
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 85
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 85
Assessing EGFR mutations. 84
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 84
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 82
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 82
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. 82
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 81
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 81
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 81
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 81
AKT1(E17K) in human solid tumours 81
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 80
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 80
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 79
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 79
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 79
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 78
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 78
Mutational profile of GNAQQ209 in human tumors. 78
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 78
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 77
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 77
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 75
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 75
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 74
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project 74
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 73
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 73
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 73
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 72
Survivin gene expression in early-stage non-small cell lung cancer. 72
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 72
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 72
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 72
Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe 72
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 71
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 71
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 71
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 71
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 70
Hypertension modulates miR-145 expression in human atherosclerotic plaques 70
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 70
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 69
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. 69
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. 69
Predictive markers in lung cancer: A few hints for the practicing pathologist 69
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 68
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. 68
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 67
p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. 67
Association between cigarette smoking and FHIT gene alterations in lung cancer. 67
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. 66
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 66
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 66
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 66
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort 65
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 64
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 64
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 63
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 63
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer 63
2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 63
K-ras mutations and cetuximab in colorectal cancer. 62
Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. 61
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 61
A percutaneous large-needle aspiration biopsy technique for histologic examination of the testis in infertile patients. 61
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 60
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 60
Jaagsiekte sheep retrovirus is not detected in human lung adenocarcinomas expressing antigens related to the Gag polyprotein of betaretroviruses. 60
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 60
Evaluation of FHIT gene alterations in ovarian cancer 59
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 59
Nucleotide and deduced amino acid sequences of tumor gene INT6. 58
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 58
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 57
Recommendations for mutational analysis of EGFR in lung carcinoma. 56
2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease 56
Totale 7.660
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.506
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.506
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.143 0 0 23 55 128 99 209 156 39 207 212 15
2020/2021933 182 15 172 7 76 189 20 10 79 130 9 44
2021/2022806 26 14 10 133 53 34 24 55 64 40 107 246
2022/20232.275 221 307 106 268 229 445 138 145 289 15 64 48
2023/20241.013 97 27 63 28 67 294 208 42 11 34 6 136
2024/20251.186 158 598 430 0 0 0 0 0 0 0 0 0
Totale 10.163